Evidence map›Paper›PMID 30992677›Full record

ArticleInfection and drug resistance2019

Cycloserine for treatment of multidrug-resistant tuberculosis: a retrospective cohort study in China.

Yang Li, Fei Wang, Limin Wu, Min Zhu, Guiqing He, Xinchang Chen, Feng Sun, Qihui Liu, Xiaomeng Wang, Wenhong Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection and drug resistance, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. A systematic review on extensively drug-resistant tuberculosis from 2009 to 2020: special emphases on treatment outcomes.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023
    Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Yang LiDepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200032, China.
Fei WangZhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang 310051, China, xmwang@cdc.zj.cn.
Limin WuHangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang 310021, China.
Min ZhuTuberculosis Treatment Center, Hangzhou Red Cross Hospital, Hangzhou 310003, China.
Guiqing HeDepartment of Infectious Diseases, Wenzhou Center Hospital, Wenzhou 325000, China.
Xinchang ChenDepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200032, China.
Feng SunDepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200032, China.
Qihui LiuDepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200032, China.
Xiaomeng WangZhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang 310051, China, xmwang@cdc.zj.cn.
Wenhong ZhangDepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200032, China.
Fudan University · CNZhejiang Center for Disease Control and Prevention · CNHangzhou Center for Disease Control and Prevention · CNHangzhou Red Cross Hospital · CNWenzhou Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCycloserine has been used in multidrug-resistant tuberculosis (MDR-TB) treatment since the 1950s. We evaluated the efficacy and safety of cycloserine and sought to clarify the role of cycloserine for treatment of simple MDR-TB, pre-extensively drug-resistant tuberculosis (pre-XDR-TB), and extensively drug-resistant tuberculosis (XDR-TB). MATERIALS AND

methodsA retrospective observational study was performed in Zhejiang Province, China. We enrolled 144 cycloserine-treated and 181 cycloserine-nontreated patients consecutively and determined the treatment outcome as the primary outcome. The proportion of patients with sputum culture conversion and the frequency of adverse drug reactions were also assessed.

resultsOne-hundred (69.4%) out of 144 patients in the cycloserine group successfully completed treatment. The HR of any unfavorable treatment outcome after the introduction of cycloserine was 0.58 (95% CI: 0.38-0.86,

conclusionCycloserine is an attractive agent for the treatment of MDR-TB, and its safety profile warrants its use in most MDR-TB cases. Cycloserine significantly improved the chance of a favorable outcome for patients with simple MDR-TB but not pre-XDR-TB and XDR-TB. Thus, more aggressive regimens might be required for pre-XDR-TB or XDR-TB patients.

Indexed as

cycloserineefficacyextensively drug-resistant tuberculosismultidrug-resistant tuberculosissafetytreatment outcome

Identifiers

PMID30992677
PMCPMC6445236
OpenAlexW2924177181

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.